
92Bio, Inc. Doses First Patient in Ph1 Trial of NTB-928 in Ovarian Cancer
July 1, 2026
Inside Arend and Buelow’s BiTE trial
August 14, 2026
92Bio, Inc. Doses First Patient in Ph1 Trial of NTB-928 in Ovarian Cancer
July 1, 2026
Inside Arend and Buelow’s BiTE trial
August 14, 2026
92Bio, Inc. Doses First Patient in Ph1 Trial of NTB-928 in Ovarian Cancer
July 1, 2026
Inside Arend and Buelow’s BiTE trial
August 14, 202692Bio Co-Founder & CEO Ben Buelow is featured in Partnology’s Biotech Leader Spotlight, sharing his journey from concept-to-clinic drug development to building 92Bio’s next generation of T-cell engagers for solid tumors.
